



**Generation of Patient Specific Reagents
for the Study of Multiple Myeloma
Tumour Progenitor Cells**

By

Felicity Louise Holbrook

**A Thesis Qualified for the Degree
of Master of Science**

**Department of Paediatrics,
The University of Adelaide,
March, 2002.**

Table of Contents

List of Abbreviations	i
List of Figures	ii
List of Tables	iii
Abstract	iv
Declaration	vi
Acknowledgements	vii
Chapter 1 : Introduction	
1.1 Multiple Myeloma	1
1.1.1 A Brief History	1
1.1.2 Disease Characteristics and Epidemiology	1
1.1.3 Diagnosis	2
1.1.4 Prognosis	3
1.1.5 Treatment	4
1.2 Monoclonal Gammopathy of Undetermined Significance	5
1.2.1 Disease Characteristics	5
1.2.2 Diagnosis	5
1.2.3 Prognosis	6
1.2.4 Treatment	6
1.3 Normal B-cell Development	6
1.4 Biology of Multiple Myeloma	8
1.4.1 Antigen Involvement	8
1.4.2 Adhesion Molecules and Signalling	9
1.5 Evidence for Tumour Progenitor Cell Involvement	10
1.5.1 Stem Cells => pre-B Cells	11
1.5.2 B-Cells => pre-Plasma Cells	13
1.6 MM vs MGUS	15
1.7 Oncogenic Events Implicated in Monoclonal Gammopathies	16
1.7.1 Numerical Abnormalities	17
1.7.2 Translocations	17
1.7.3 Base Modifications	21
1.7.4 Other Mechanisms Supporting Myeloma Cell Growth	22
1.7.5 Summary of Genetic Lesions Implicated in Multiple Myeloma	23
1.8 Objectives	25

Chapter 2 : Materials, Reagents and Solutions

2.1	Overview	26
2.2	Patient Material	26
2.3	Bacterial Strains	26
2.4	Mammalian Cell Lines	27
2.5	Immunochemistry Reagents	27
2.5.1	Commercial Conjugates and Antibodies	27
2.5.2	Hybridoma Supernatants	27
2.6	Buffers	28
2.6.1	Agarose Gel Loading Buffer	28
2.6.2	Blocking Buffer (7-mer Peptide Library)	28
2.6.3	Electrophoresis Sample Buffer (ESB)	29
2.6.4	Periplasmic Extraction Buffer (Borate Buffer)	29
2.6.5	Phosphate Buffered Saline (20x PBS), PBS-Azide and PBS-Tween	29
2.6.6	0.5M Phosphate-Citrate Buffer	30
2.6.7	20mM Phosphate / 10mM EDTA Buffer, pH 7.0	30
2.6.8	Tris Borate EDTA Buffer (10x TBE)	30
2.6.9	Tris-Buffered Saline	30
2.7	Reagents & Solutions	31
2.7.1	Anti-Phage Solution (1% SDS / 0.1M NaOH)	31
2.7.2	4-chloro-1-naphthol	31
2.7.3	Phage Precipitation Solution	32
2.7.4	o-Phenylene Diamine	32
2.7.5	Red Cell Lysing Solution (10x)	32
2.7.6	SDS-Polyacrylamide Gels	32
2.8	Growth Media	33
2.8.1	Bacterial	33
2.8.1.1	Antibiotics	33
2.8.1.2	1M IPTG	33
2.8.1.3	2YT	34
2.8.1.4	LB	34
2.8.1.5	Nutrient Agar	34
2.8.1.6	Agarose Top	35
2.8.1.7	IPTG-XGal Plates	35
2.8.2	Mammalian Cell Culture	35
2.8.2.1	Heat Inactivated Fetal Bovine Serum	35
2.8.2.2	Penicillin, Streptomycin, Glutamine (100x PSG)	36
2.8.2.3	RF10	36
2.8.2.4	Freezing Media	36
2.8.2.5	HAT Media	36
2.8.2.6	HT Media	37
2.9	Supplier Information	37

Chapter 3 : Evaluation of Traditional Hybridoma Techniques for the Generation of Anti-Idiotypic Monoclonal Antibodies

3.1	Overview	38
3.2	Introduction	38
3.3	Methods	41
3.3.1	Preparation of Myeloma Paraprotein Fab	41
3.3.1.1	Purification of Patient Paraprotein	41
3.3.1.2	Protein Determination	41
3.3.1.3	Papain Digest	42
3.3.1.4	SDS-Polyacrylamide Gel Electrophoresis	42
3.3.1.5	Western Blotting	43
3.3.2	Monoclonal Antibody Production	43
3.3.2.1	Immunisation	44
3.3.2.2	Tolerisation – 1	44
3.3.2.3	Tolerisation – 2	44
3.3.2.4	Anti-Idiotypic ELISA	45
3.3.2.5	Spleen Single Cell Suspension	45
3.3.2.6	Polyethylene Glycol Fusion	46
3.3.2.7	Plating	46
3.3.2.8	Cloning	46
3.3.2.9	Expansion, Storage and Thawing	47
3.4	Results	47
3.4.1	Preparation of Patient Paraprotein Fab	47
3.4.2	Hybridoma Production – Standard Immunisation	50
3.4.3	Tolerisation of Balb/C Mice Towards Human Immunoglobulin	53
3.5	Discussion	54

Chapter 4 : Discovery of Paraprotein Mimotopes from Linear Phage Display Peptide Libraries

4.1	Overview	59
4.2	Introduction	59
4.3	Methods	61
4.3.1	Random Peptide Phage-Displayed Libraries	61
4.3.2	Panning Against Immobilised Target Paraproteins	61
4.3.3	Phage Amplification	62
4.3.4	Phage Precipitation	62
4.3.5	Phage Count Determination	63
4.3.6	Phage ELISA	63
4.3.7	Phage Cloning and Sequencing	64
4.3.8	Panning in Solution	65
4.3.9	Plaque Assay	66
4.3.10	BIACore Analysis of Biotinylated Synthetic Peptides	66
4.4	Results	67
4.4.1	Panning Against Immobilised Paraprotein	67

4.4.2	Panning in Solution	68
4.4.3	Identification of Isolated Peptide Motifs	69
4.4.4	BIAcore Analysis of Synthetic Peptides	70
4.4.5	Analysis of the Binding Specificity of P3-20, P4-7 and P6-15 Expressing Phage Clones	70
4.5	Discussion	74
Chapter 5 : Design of g3p Fusion Proteins in an Attempt to Recover Peptide Function		
5.1	Overview	80
5.2	Introduction	80
5.3	Methods	81
5.3.1	Design of Recombinant g3p Fusion Proteins	81
5.3.2	Primers	83
5.3.3	Polymerase Chain Reaction: g3p-D1 and g3p-D1D2	83
5.3.4	Restriction Enzyme Digests	86
5.3.5	Ligation Reactions	86
5.3.6	Heat-Shock Transformation	87
5.3.7	Selection of g3p-D1 and g3p-D1D2 Clones	87
5.3.8	Expression and Recovery of Recombinant Proteins	87
5.3.9	Slot Blot Analysis	88
5.3.10	BIAcore Analysis – NiNTA Biosensor Chip	88
5.4	Results	89
5.4.1	Cloning of g3p-D1 and g3p-D1D2	89
5.4.2	Expression of Recombinant g3p Fusion Proteins	90
5.4.3	BIAcore Analysis of Recombinant g3p	91
5.5	Discussion	93
Chapter 6 : Discussion		
6.1	Summary and Conclusions	95
6.2	Reassessment of the “Prime Target”	99
Appendix : DNA sequence of the minor coat protein (g3p) of fd bacteriophage		101
Bibliography		102

List of Abbreviations

3'	three prime
5'	five prime
APS	ammonium persulphate
Az	sodium azide
bp	base pair
BSA	bovine serum albumin
DMSO	dimethylsulphoxide
DNA	deoxyribonucleic acid
dNTP	deoxynucleotide triphosphate
ECL	enhanced chemi-luminescence
EDTA	ethylenediamine tetra-acetic acid
ELISA	enzyme linked immunosorbent assay
Fab	fragment antigen binding
FBS	fetal bovine serum
g	centrifugal force
g3p	gene III coat protein of filamentous bacteriophage
HRP	horse-raddish peroxidase
i.p.	intraperitoneal
i.v.	intravenous
IgG	immunoglobulin, γ isotype
IPTG	isopropylthio- β -D-galactopyranoside
kDa	kilodalton
mAb	monoclonal antibody
MW	molecular weight
nm	nanometre
NTA	nitrilotriacetic acid
OD	optical density
OPD	o-phenylene diamine
PAGE	polyacrylamide gel electrophoresis
PBS(-T)	phosphate buffered saline (-Tween)
PEG	polyethylene glycol
pfu	plaque forming units
rpm	revolutions per minute
RU	resonance units
SA	streptavidin
scFv	single chain variable fragment
SDS	sodium dodecyl sulphate
TBS(-T)	tris buffered saline (-Tween)
tu	transducing units
UV	ultraviolet
V	volts
V _H	heavy chain variable region
V _L	light chain variable region
X-Gal	5-bromo-4-chloro-3-indolyl- β -D-galactoside

List of Figures

1.1	B-cell developmental pathway in relation to immunoglobulin gene sequence	7
1.2	Flow diagram of the possible mutational evolution of multiple myeloma	24
3.1	Serum gel electrophoresis of purified patient paraproteins	48
3.2	Silver-stained SDS-PAGE analysis of purified whole and papain-digested paraprotein	49
3.3	Serum anti-paraprotein response three days post boosting with patient Fab fragments	50
3.4	Western blot analysis of 1D11E and 1E5B against 4 μ g reduced normal human immunoglobulin	52
3.5	Comparison of serum anti-Ig antibodies following tolerisation as determined by ELISA	53
4.1	Summary of ELISA data following panning of the 20-mer peptide library	67
4.2	Summary of ELISA data following panning of the 15-mer peptide library	68
4.3	Summary of ELISA data following panning of the 7-mer library against paraproteins from patients 1, 2, 4 & 5	69
4.4	Demonstration of the binding of P3 paraprotein but not unrelated immunoglobulin to P3-20 peptide by BIAcore analysis	71
4.5	BIAcore analysis of the P6-15 peptide	72
5.1	Schematic representation of the construction of g3p-D1 and g3p-D1D2 recombinant proteins	82
5.2	Locations of primer annealment to g3p-peptide fusion genes	84
5.3	Amplification of P3-20 g3p-D1 and g3p-D1D2 inserts from <i>E. coli</i> infected with P3-20 expressing phage	90
5.4	Slot blot analysis of g3p-D1 and g3p-D1D2 fusion protein expression	91
5.5	Assessment of the suitability of BIAcore analysis for the detection of binding between recombinant proteins immobilised to Ni-NTA <i>via</i> 6-His and a monoclonal antibody directed against a unique peptide motif	92

List of Tables

2.1	SDS-polyacrylamide gel recipes	33
3.1	Paraprotein subclass determination	49
3.1	Binding analysis of supernatant from antibody-producing primary fusion wells	51
4.1	Paraprotein, corresponding peptide and number of clones sequenced	69
4.2	ELISA reactivity of phage clones expressing P3-20, P4-7 and P6-15 against 1 μ g target or unrelated paraprotein	72
4.3	ELISA reactivity of phage expressing P3-20 and naïve 20-mer library phage against 1 μ g P3 paraprotein or normal human IgG ₂ control antibody	72
5.1	Primers used for the amplification of patient specific g3p-D1 and g3p-D1D2	83

Abstract

Hybridoma production was investigated as a means to produce patient specific reagent for the characterisation of putative tumour precursors in multiple myeloma. Purified Fab fragments were used as immunogen so as to avoid an immune response towards antigenic regions within the Fc. However, all of the paraprotein-reactive murine antibodies isolated also demonstrated reactivity against pooled normal human immunoglobulin. Induction of tolerance towards human immunoglobulin was investigated as a means focus the immune response towards idiotypic determinants. Although successful in ablating the response towards unrelated immunoglobulins, serum antibody response against immunising paraprotein was also absent.

Three linear libraries were screened against a total of six IgG patient paraproteins, either as immobilised targets or in solution. Three different peptides were recovered (P3-20, P6-15 and P4-7), each of which recognised a different patient paraprotein. All three peptides exhibited binding in ELISA to the original target paraprotein and an absence of binding to normal human immunoglobulin or unrelated paraprotein when expressed by phage. P3-20 retained its binding characteristics in synthetic form, as determined by surface plasmon resonance. However, P6-15 and P4-7 failed to bind to their respective targets as synthetic peptides. The loss of function for P6-15 (VLLFHEPAGLPVYFW) may be attributed to the highly hydrophobic nature of this motif.

It was hypothesised that the presence of structural elements within the minor coat protein were required for P6-15 to adopt the appropriate conformation for binding to target paraprotein. Recombinant proteins were engineered containing the peptide sequence fused to the first N-terminal domain of g3p. Expressed protein did not exhibit the desired binding to paraprotein and neither did a second recombinant protein containing the first and second

domains together. P3-20 expressed as recombinant g3p fusion proteins also failed to bind to its target.

In conclusion, this work has demonstrated the value of phage-displayed peptide libraries for the generation of reagents specific towards myeloma tumour paraproteins. It is reasonable to predict that the extension of this work with additional patient subjects would enable exciting research into the true nature of the malignant precursor involved in multiple myeloma.

Declaration

This work contains no material which has been accepted for the award of any degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being available for loan and photocopying.

Felicity Louise Holbrook

B. Biotech. (Hons.)

Acknowledgements

I would not have been having the pleasure to sit here and write this page now if it wasn't for a number of people:

First of all I wish to extend by deepest thanks and gratitude to my principal supervisor, Professor Heddy Zola. You have guided me through the past three years and seen me through to the end with a smile regardless of the situation. Many thanks also to my other supervisor, Doctor Ian Nicholson, without whom I may have had to introduce our BIAcore system to an untimely demise. I also wish to acknowledge the CRC for Diagnostics for providing my scholarship and the Child Health Research Institute, where this research was based.

I would like to thank Dr. Andrew Zannettino (Division of Haematology, IMVS) for fitting me into his ever-hectic schedule and for his help with the clinical aspects of this project. Also, thanks to Dr. Mick Foley (La Trobe University, Victoria) for suggesting I come and play with their peptide libraries and to Felomena Li for her guidance while I was there.

To Deb, Tanja, Michaela, Hannah and Mandyyour friendship has made the bad days worth fronting up to (the tech support was an added bonus), and to Poon thanks for the new dimension you added to everyday life in the lab.

Lastly to my parents, your love and support has been invaluable ... and a special thankyou to Glen, for your understanding and tolerance and for always being there when I needed you.